Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYFORM-008: Favezelimab/Pembrolizumab vs Chemotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma
NCT05508867Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2022
- Primary completion
- Sep 2025
- Modality
- Monoclonal Antibodies
- Countries
- 20
01
Overview
Phase 2, randomised, open-label trial of favezelimab and pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival. Started Oct 2022; status: completed.
02
Drugs
favezelimabpembrolizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT05508867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05508867.